CD133 antigen peptide-pulsed autologous dendritic cell vaccine

{
  "id": "MLC-T-ONC-012363",
  "term": "CD133 antigen peptide-pulsed autologous dendritic cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen, with potential antineoplastic activity. Upon intradermal administration, the CD133 antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and progenitor cells and overexpressed on many types of cancer cells; it is associated with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells. Epitope design that is restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.",
  "synonyms": [
    "CD133 DC vaccine",
    "CD-133 dendritic cell vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cd133-antigen-peptide-pulsed-autologous-dendritic-cell-vaccine/"
}